BiondVax Pharmaceuticals Ltd (ADR)(NASDAQ:BVXV) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during Pre-market on Nov 28, 2016. Earnings per share were $0.01.
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd. the commercial arm of the Weizmann Institute Israel for developing manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine designed to provide multi-season and multi-strain protection against some human influenza virus strains including both seasonal and pandemic flu strains. Its technology utilizes a combination of conserved epitomes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. The Company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.